# OnCo record paper-psmafore-lancet-2024 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-psmafore-lancet-2024/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-psmafore-lancet-2024" ;
  schema:name "177 Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial"@en ;
  schema:description "Published report from the PSMAfore trial registered as NCT04689828, in The Lancet (2024), chosen as the most cited paper whose own text cites the registry id."@en ;
  schema:url <https://onco.cc/key-papers/paper-psmafore-lancet-2024/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/s0140-6736(24)01653-2>, <https://pubmed.ncbi.nlm.nih.gov/39293462/>, <https://europepmc.org/article/MED/39293462>, <https://clinicaltrials.gov/study/NCT04689828> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1016/s0140-6736(24)01653-2> ;
  schema:datePublished "2024"^^xsd:gYear ;
  schema:author "Morris MJ, Castellano D, Herrmann K, et al." ;
  onco:trials <https://onco.cc/trials/psmafore/> ;
  onco:journals <https://onco.cc/journals/lancet/> .